Collegium Pharmaceutical
COLL
Constellation Brands
STZ
Ermenegildo Zegna NV
ZGN
DexCom
DXCM
Workday
WDAY
US Stock MarketDetailed Quotes
EYPT EyePoint Pharmaceuticals
- 8.530
- -0.290-3.29%
Close Jan 24 16:00 ET
- 8.530
- 0.0000.00%
Post 20:01 ET
582.18MMarket Cap-4.29P/E (TTM)
8.795High8.380Low339.85KVolume8.710Open8.820Pre Close2.91MTurnover0.73%Turnover RatioLossP/E (Static)68.25MShares30.99052wk High2.66P/B398.03MFloat Cap6.90052wk Low--Dividend TTM46.66MShs Float72.200Historical High--Div YieldTTM4.71%Amplitude2.190Historical Low8.555Avg Price1Lot Size
EyePoint Pharmaceuticals News
EyePoint Pharmaceuticals | 8-K: Current report
EyePoint Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Sanders Reginald J.
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Sanders Reginald J.
EyePoint Pharmaceuticals | 8-K: Current report
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Hassan Fred
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director ANDO GORAN
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Duty Stuart
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director DICICCO WENDY F
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Ribeiro Ramiro
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Elston George
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Lurker Nancy
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Landis John B.
EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Duker Jay S.
EyePoint Pharmaceuticals | 8-K: Current report
EyePoint Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Cormorant Asset Management, LP(12.20%),Bihua Chen(12.20%)
EyePoint Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-T. ROWE PRICE ASSOCIATES, INC.(4.7%)
EyePoint Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(5.69%)
EyePoint Pharmaceuticals | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Adage Capital Management, L.P.(7.08%),Robert Atchinson(7.08%), etc.
EyePoint Pharmaceuticals | SC 13G: Statement of acquisition of beneficial ownership by individuals-BlackRock, Inc.(7.8%)